[{"id":"03e7603a-1cd4-4afe-8a3c-0dc20e27234c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02521844","created_at":"2021-01-18T12:11:30.833Z","updated_at":"2024-07-02T16:35:30.025Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours","source_id_and_acronym":"NCT02521844","lead_sponsor":"EDDC (Experimental Drug Development Centre), A*STAR Research Entities","biomarkers":" RSPO2 • RSPO3","pipe":" | ","alterations":" RSPO3 fusion","tags":["RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RSPO3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ETC-159"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-11-08"}]